This page shows the latest Stelara news and features for those working in and with pharma, biotech and healthcare.
Amgen has announced preliminary results from a phase 3 study evaluating the efficacy and safety of its drug candidate ABP 654 compared to Janssen’s Stelara in adult patients with moderate ... The study evaluated the percentage improvement from baseline
J&J already has high stakes in the autoimmune disease market, with some of its existing products, including psoriasis med Stelara (ustekinumab), already reaching blockbuster status.
J&J already has high stakes in the anti-inflammatory market, with its blockbuster IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab) and follow-up Tremfya (guselkumab). ... The therapy is a follow-up to its older blockbuster Stelara, which is facing
This includes a recent phase 3 BE VIVID study comparing the drug to Johnson &Johnson’s Stelara (ustekinumab), which bimekizumab also demonstrated superiority over.
First approved in Europe two years ago, Tremfya (guselkumab) is the follow-up to J&J’s IL-12/IL-23 inhibitor blockbuster Stelara (ustekinumab), which is facing increased competition across ... of Stelara – which made $4.66bn in the first three
showed it was better at clearing skin than placebo and Johnson &Johnson’s big-selling Stelara (ustekinumab) product.
More from news
Approximately 15 fully matching, plus 74 partially matching documents found.
The analysis concentrated on patient-reported outcomes data from two studies that compared risankizumab to J&J’s $4bn-a-year IL-12/IL-23 inhibitor Stelara (ustekinumab) and one against ... The analysis showed that 56% of patients on risankizumab were
Just last month it was a 'patient access scheme' that brought Stelara (ustekinumab) NICE approval in psoriatic arthritis after the company agreed to provide the 90 mg dose (two vials) of ... Stelara at the same cost as the 45 mg dose (one vial) for
Likewise, J&J had a strong year - with eight of its key products, including Zytiga, Xarelto, Remicade, Stelara and Invega Sustenna/Xeplion, driving collective growth of more than $3.5bn (10
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Healthcare is evolving rapidly. To stand out from the crowd requires a potent combination of rich insight, innovative ideas and...